ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, this data and our previous work on GAB2 also highlights the possibility that GAB2, as a common player in BCR::ABL1 and MC signaling could serve as an additional target in the treatment of CML.